Zentalis Pharmaceuticals, Inc.
ZNTL · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $84 | $114 | $216 |
| - Cash | $39 | $38 | $42 | $34 |
| + Debt | $37 | $38 | $39 | $40 |
| Enterprise Value | – | $84 | $111 | $222 |
| Revenue | $0 | $0 | $0 | $27 |
| % Growth | – | – | -100% | – |
| Gross Profit | $0 | $0 | $0 | $27 |
| % Margin | – | – | – | 100% |
| EBITDA | -$27 | -$35 | -$38 | -$46 |
| % Margin | – | – | – | -170.5% |
| Net Income | -$27 | -$27 | -$48 | -$47 |
| % Margin | – | – | – | -176.7% |
| EPS Diluted | -0.37 | -0.37 | -0.67 | -0.67 |
| % Growth | 0% | 44.8% | 0% | – |
| Operating Cash Flow | -$27 | -$35 | -$33 | -$40 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$27 | -$35 | -$33 | -$40 |